Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy

BACKGROUND: To observe efficacy of the anti-CD22 chimeric antigen receptor modified (anti-CD22-CAR) T cell salvage therapy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and B cell acute lymphoid leukemia (B-ALL) patients whose disease did not reach CR or progressed again after a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Haibo, Deng, Haobin, Mu, Juan, Lyu, Cuicui, Jiang, Yanyu, Deng, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259947/
https://www.ncbi.nlm.nih.gov/pubmed/34239307
http://dx.doi.org/10.2147/OTT.S312904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259947/
https://www.ncbi.nlm.nih.gov/pubmed/34239307
http://dx.doi.org/10.2147/OTT.S312904

Ejemplares similares